Share on StockTwits

Insys Therapeutics (NASDAQ:INSY) Director Theodore H. Stanley acquired 3,000 shares of Insys Therapeutics stock on the open market in a transaction dated Wednesday, August 13th. The stock was purchased at an average cost of $33.93 per share, with a total value of $101,790.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $33,930. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Insys Therapeutics (NASDAQ:INSY) traded up 6.28% during mid-day trading on Friday, hitting $34.70. 591,503 shares of the company’s stock traded hands. Insys Therapeutics has a 1-year low of $15.96 and a 1-year high of $57.9133. The stock’s 50-day moving average is $28.36 and its 200-day moving average is $34.70. The company has a market cap of $1.190 billion and a P/E ratio of 22.67.

Insys Therapeutics (NASDAQ:INSY) last released its earnings data on Tuesday, August 12th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.28. The company had revenue of $55.70 million for the quarter, compared to the consensus estimate of $52.77 million. On average, analysts predict that Insys Therapeutics will post $1.08 earnings per share for the current fiscal year.

Insys Therapeutics, Inc, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care.

Receive News & Ratings for Insys Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.